Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
Nearly 7,000 excess deaths from tuberculosis occurred in the WHO European Region in the three years of the pandemic from 2020 - 2022, compared to what experts had expected based on pre-2020 estimates.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
To assess the level of preparedness of EU/EEA Member States to respond to zoonotic avian flu outbreaks, ECDC has carried out two surveys - one assessing the laboratory capacity for molecular diagnosis and characterisation of zoonotic influenza viruses, and the other focusing on measures applied to protect exposed people during outbreaks of highly pathogenic avian influenza.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.